Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Pak J Pharm Sci ; 37(1(Special)): 199-203, 2024 Jan.
Article in English | MEDLINE | ID: mdl-38747270

ABSTRACT

This study investigates the combined effect of vitamin C and chromium on BMI, lipid profile, LFTs and HbA1c of Diabetes Mellitus type 2 patients. This is randomized controlled trial study. For this study a total of 60 patients (n=28 female, n=32 male) Diabetes Mellitus type 2 patients were selected. They were divided into treatment group (vitamin C (500mg) Chromium (200µg) and control group (placebo) comprising thirty patients per group. Mean age in control group and treatment group is 33± 5.729 and 33±7.017 respectively. Statistical analysis showed significant results of lipid profile; total cholesterol (mg/dl) 198±66.1 P=0.008, High-Density Lipoprotein 38±7.5, P<0.001, Low Density Lipoprotein (LDL) (mg/dl) 105.1±22.4, P=0.002 and Triglycerides 191±64.3, P=0.02 are respectively. Levels of serum ALT (u/l) (34.7±9.1, P<0.001) and AST (u/l) (31.6 ±8.6, P<0.001) were significantly lower as compared to control group. HbA1c percentages were also normalized (5.45±0.2, P<.001) as compared to group 2. BMI values were also improved (P=0.01) after treatment. Combined supplementation of vitamin C and chromium reduce the plasma lipid percentage, blood glucose levels and also improve the ALT and AST functions.


Subject(s)
Ascorbic Acid , Body Mass Index , Chromium , Diabetes Mellitus, Type 2 , Glycated Hemoglobin , Humans , Female , Male , Ascorbic Acid/therapeutic use , Chromium/therapeutic use , Adult , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/drug therapy , Glycated Hemoglobin/metabolism , Hyperglycemia/drug therapy , Hyperglycemia/blood , Hyperlipidemias/drug therapy , Hyperlipidemias/blood , Lipids/blood , Liver/drug effects , Liver/enzymology , Liver/metabolism , Blood Glucose/drug effects , Blood Glucose/metabolism , Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Middle Aged
2.
Pak J Pharm Sci ; 36(6(Special)): 1901-1908, 2023 Nov.
Article in English | MEDLINE | ID: mdl-38264896

ABSTRACT

Vitamin D supports the immune system fight TB by inhibiting Interferon-gamma (IFN-γ) and lowering host inflammation. The purpose of the research was to see if giving the vitamin D supplements to TB patients affected their prognosis. A randomized placebo control study of 200 TB patients was performed among which 106 received 400,000 IU of injectable vitamin D3 and 94 received placebo for 2 doses. Assessment was carried out at the end of every month for 3 months. IFN-γ responses to whole blood stimulation generated by the Mycobacterium tuberculosis sonicate (MTBs) antigen and early secreted and T cell activated 6 kDa (ESAT6) were assessed at 0 and 12 weeks. The statistical analysis used descriptive statistics (mean and standard deviation), Friedman's test and Fisher's test. The vitamin D group gained significantly more weight (+3.90 pounds) and had less persistent lung disease on imaging (1.33 zones vs. 1.84 zones). They also had a 50% decrease in cavity size. Additionally, patients with low baseline serum concentrations of 25-(OH)D had a significant increase in MTB-induced IFN-γ production after taking vitamin D supplements. Vitamin D administration in large amounts can hasten the recovery of TB patients. The findings point is a therapeutically useful activity of Vitamin D's in the management for tuberculosis.


Subject(s)
Mycobacterium tuberculosis , Tuberculosis , Humans , Vitamins , Vitamin D , Dietary Supplements , Interferon-gamma
SELECTION OF CITATIONS
SEARCH DETAIL
...